Oncology Briefings™: Managing Pneumonitis in Patients with Stage III NSCLC

Release Date: December 30, 2018
Expiration Date: December 30, 2019
Media: Internet - based

Activity Overview

This activity, Oncology Briefings™: Managing Pneumonitis in Patients with Stage III NSCLC, developed in Physicians’ Education Resource, LLC^® established Oncology Briefings™ legacy format, is an online interactive monograph that provides treatment strategies for patients with pneumonitis secondary to non-small cell lung cancer (NSCLC). This presentation features a national thought leader, Roy S. Herbst, MD, PhD, who provides key insights.

Benefits of Participating

• Learn about new standards of care for the treatment of immune checkpoint inhibitor (ICPi)–induced pneumonitis in NSCLC
• Find out how experts diagnose and manage ICPi-induced pneumonitis
• Gain insight into emerging therapies for predicting patients at high risk of developing pneumonitis and prevention strategies

Acknowledgement of Commercial Support

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

Target Audience

This educational initiative is directed toward oncology healthcare professionals involved in the treatment and management of patients with non-small cell lung cancer (NSCLC), including medical oncologists, surgical oncologists, and pulmonologists. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the management of patients with NSCLC are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Determine how multidisciplinary team approaches can be promulgated to identify pneumonitis in patients with stage III NSCLC
• Characterize pneumonitis in the context of the application of chemoradiotherapy and immune checkpoint inhibitor (ICPi) utilization in patients with lung cancer
• Apply clinical trial and practical experience with the use of ICPis in patients with NSCLC to optimize management

Faculty, Staff, and Planners' Disclosures

Faculty

Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Associate Director for Translational Research
Yale Cancer Center, Smilow Cancer Hospital
New Haven, CT

Disclosures: Consultant: AbbVie Pharmaceuticals, AstraZeneca, Biodesix, Bristol-Myers Squibb, Eli Lilly and Company, EMD Serono, Genentech/Roche, Heat Biologics, Jun Shi Pharmaceuticals, Loxo Oncology, Merck and Company, Nektar, NextCure, Novartis, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, Symphogen, TESARO; Research Support: AstraZeneca, Eli Lilly and Company, Merck and Company; Scientific Advisory Board: Neon Therapeutics, Infinity Pharmaceuticals, NextCure

The staff of PER^® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER^® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER^® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER^® is required by ACCME to resolve all COI. PER^® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^®.